{"id":108423,"date":"2024-05-23T12:08:59","date_gmt":"2024-05-23T12:08:59","guid":{"rendered":"https:\/\/www.atlasrleye.com\/?page_id=108423"},"modified":"2024-12-18T10:13:49","modified_gmt":"2024-12-18T10:13:49","slug":"clinical-case-6","status":"publish","type":"page","link":"https:\/\/www.atlasrleye.com\/en\/proliferative-diabetic-retinopathy-in-type-2-diabetes\/clinical-case-6\/","title":{"rendered":"Clinical Case 6"},"content":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”DIABETIC RETINOPATHY” font_container=”tag:h5|font_size:22px|text_align:center|color:%23000000″ use_theme_fonts=”yes” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fretinopatia-diabetica%2F|title:Diabetic%20Retinopathy|”][vc_text_separator title=”” i_icon_fontawesome=”fas fa-eye” i_color=”custom” i_size=”lg” color=”custom” border_width=”8″ css=”.vc_custom_1637080776101{margin-bottom: -5px !important;}” add_icon=”true” accent_color=”#bababa” i_custom_color=”#bababa”][vc_custom_heading text=”Proliferative Diabetic Retinopathy in Type 2 Diabetes – Clinical Case 06″ font_container=”tag:h1|text_align:center|color:%235f1b52″ use_theme_fonts=”yes” css=”” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fen%2Fproliferative-diabetic-retinopathy-in-type-2-diabetes%2F|title:PROLIFERATIVE%20DIABETIC%20RETINOPATHY%20IN%20TYPE%202%20DIABETES|”]

<\/div>[\/vc_column][\/vc_row][vc_row][vc_column]
<\/div>
<\/div>[\/vc_column][\/vc_row][vc_row gap=”35″ equal_height=”yes”][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108436″ img_size=”270×270″ alignment=”center” onclick=”link_image” css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

60-year-old patient diagnosed with diabetes 20 years ago.Proliferative diabetic retinopathy RLE. Currently HbA1c 6.5%. VA: SPL RE, 20\/200 LE. Severe fibrovascular proliferation in LE.<\/span><\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108440″ img_size=”270×270″ alignment=”center” onclick=”link_image” css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Three years after surgery (phacoemulsification with IOL implantation; vitrectomy, removal of fibrovascular tissue and laser photocoagulation). Macular epiretinal membrane. BCVA: 20\/28 LE.<\/span><\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n

Evaluations
\n<\/span><\/h3>\n

[\/vc_column_text][vc_tta_accordion active_section=”99″ no_fill=”true” collapsible_all=”true”][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”1st Evaluation – 15 07 2021″ tab_id=”1661528679639-01942171-9860″][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Fluorescein Angiography<\/p>\n

\n

Multiple ischemic areas, retinal neovascularization and leakage at optic disc.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102160,102164,102168,102198,102203″ img_size=”193×206″ css=”.vc_custom_1716466100792{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/3″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102189,102193″ img_size=”183×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/3″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102223,102227″ img_size=”183×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/3″][vc_column_text]<\/p>\n

\n
\n

Red-free<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102215,102219″ img_size=”183×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”2\/3″][vc_column_text css=”.vc_custom_1716466410688{margin-top: -30px !important;}”]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

RE: pseudophakic; AV NLP; neovascularization of angle; PIO 45mmHg.<\/span><\/p>\n

LE: cataract; AV 20\/200 LE; no neovascularization of the iris; PIO 10mmHg.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102172,102176″ img_size=”323×206″ css=”.vc_custom_1716466572787{margin-top: -30px !important;}”][\/vc_column_inner][vc_column_inner width=”1\/3″][vc_column_text css=””]<\/p>\n

\n
\n

Visumetry<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102207″ img_size=”350×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102136,102140,102144,102148,102152,102156″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

\n

Severe fibrovascular proliferation in LE.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102180,102185,102211″ img_size=”251×206″ css=”.vc_custom_1716466050901{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”2nd Evaluation – postoperative – 26 08 2021″ tab_id=”1661787125818-dcac15f9-295e”][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102256″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102248″ img_size=”193×206″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102231,102236,102240,102244″ img_size=”307×110″ css=””][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

\n

One month after surgery (phacoemulsification with IOL implantation; vitrectomy, removal of fibrovascular tissue and laser photocoagulation). BCVA: 20\/22 LE. Peripheral ischemia.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102252″ img_size=”251×206″ css=”.vc_custom_1716466329926{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”3rd Evaluation – 15 12 2022″ tab_id=”1661787445532-f61f08ca-e2dc”][vc_row_inner][vc_column_inner width=”1\/5″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102280″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102264″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”3\/5″][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

RE: neovascularization of the iris.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102268,102272″ img_size=”283×206″ css=”.vc_custom_1716466756023{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n

\n

Macular epiretinal membrane.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102284,102288,102292,102260″ img_size=”307×110″ css=”.vc_custom_1716466728818{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102276″ img_size=”251×206″ css=””][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][vc_tta_section i_icon_fontawesome=”far fa-calendar-alt” add_icon=”true” title=”4th Evaluation – 04 01 2024″ tab_id=”1716466936099-35a6b232-cd2a”][vc_row_inner][vc_column_inner width=”1\/5″][vc_column_text]<\/p>\n

\n
\n

Autofluorescence<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102320″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”1\/5″][vc_column_text]<\/p>\n

\n
\n

Infrared<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102304″ img_size=”193×206″ css=””][\/vc_column_inner][vc_column_inner width=”3\/5″][vc_column_text css=””]<\/p>\n

\n
\n

Anterior Segment Photo<\/p>\n

\n

RE: neovascularization of the iris. LE: pseudophakic; BCVA: 20\/28 LE.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102308,102312″ img_size=”283×206″ css=”.vc_custom_1716467715556{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

OCT (B-Scan) longitudinal<\/p>\n

\n

Macular epiretinal membrane.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102324,102328,102296,102300″ img_size=”307×110″ css=”.vc_custom_1716467744350{margin-top: -30px !important;}”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

\n
\n

Colour retinography<\/p>\n

[\/vc_column_text][vc_gallery type=”image_grid” images=”102316″ img_size=”251×206″ css=”.vc_custom_1716467767550{margin-top: 30px !important;}”][\/vc_column_inner][\/vc_row_inner][\/vc_tta_section][\/vc_tta_accordion][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p><\/div>\n<\/div>\n

[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_custom_heading text=”DIABETIC RETINOPATHY” font_container=”tag:h5|font_size:22px|text_align:center|color:%23000000″ use_theme_fonts=”yes” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fretinopatia-diabetica%2F|title:Diabetic%20Retinopathy|”][vc_text_separator title=”” i_icon_fontawesome=”fas fa-eye” i_color=”custom” i_size=”lg” color=”custom” border_width=”8″ css=”.vc_custom_1637080776101{margin-bottom: -5px !important;}” add_icon=”true” accent_color=”#bababa” i_custom_color=”#bababa”][vc_custom_heading text=”Proliferative Diabetic Retinopathy in Type 2 Diabetes – Clinical Case 06″ font_container=”tag:h1|text_align:center|color:%235f1b52″ use_theme_fonts=”yes” css=”” link=”url:https%3A%2F%2Fwww.atlasrleye.com%2Fen%2Fproliferative-diabetic-retinopathy-in-type-2-diabetes%2F|title:PROLIFERATIVE%20DIABETIC%20RETINOPATHY%20IN%20TYPE%202%20DIABETES|”][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row][vc_row gap=”35″ equal_height=”yes”][vc_column width=”1\/2″][vc_row_inner][vc_column_inner width=”1\/2″][vc_single_image image=”108436″ img_size=”270×270″ […]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":75341,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-108423","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/comments?post=108423"}],"version-history":[{"count":8,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108423\/revisions"}],"predecessor-version":[{"id":114306,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/108423\/revisions\/114306"}],"up":[{"embeddable":true,"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/pages\/75341"}],"wp:attachment":[{"href":"https:\/\/www.atlasrleye.com\/en\/wp-json\/wp\/v2\/media?parent=108423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}